POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed
Executive Summary
Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.
You may also be interested in...
CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
Bristol Projects Opdivo Sales Will Grow Again In 2021
With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.
Merck Confident In Keytruda’s Dominance In Lung Cancer, Despite Competitors’ Data
With Keytruda sales of more than $3bn during Q3 and roughly 80% market share in lung cancer, Merck indicates little worry about recent data readouts for BMS and AstraZeneca in NSCLC.